ROCKVILLE, Md., March 4, 2026 /PRNewswire/ — REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations on its RGX-202 investigational gene therapy for Duchenne muscular dystrophy at the 2026 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results